-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, under the background of the country's strong support for pharmaceutical innovation, it has become a consensus in the industry that companies have the ability to independently research and develop innovative drugs to stand out from the competition in the industry, and that innovation capabilities are a company's strong core competitiveness
.
However, it is worth noting that although pharmaceutical companies are currently engaged in innovative research and development, due to the uneven innovation and research capabilities of pharmaceutical companies and the huge investment in innovative drug research and development, many companies have also begun to introduce new drugs to enrich their product pipelines.
, And enhance innovation competitiveness
.
For example, Xin Li Thai announced a cooperation with South Korea D&DPharmatech, Inc.
to obtain the exclusive license for its innovative drug DD01 in mainland China
.
It is understood that "DD01" is a long-acting GLP-1R/GCGR dual agonist developed by D&D.
The proposed development indications are type II diabetes, obesity, non-alcoholic steatohepatitis (NASH) and other diseases
.
Currently, DD01 is conducting a phase I clinical trial in the United States with subjects with non-alcoholic fatty liver disease and obese type 2 diabetes
.
According to the announcement, after the start of the cooperation, Xinlitai will use self-raised funds to pay according to the development milestone.
The total amount is expected to be less than 27 million U.
S.
dollars (a total of approximately RMB 175.
5 million, subject to the exchange rate conversion amount at the time of actual investment)
.
Coincidentally, not long before this, Yiyi Biosciences and CP Tianqing Nanjing Shunxin jointly announced the new biological drug F-627 (Aibeguestine α, long-acting) for the treatment of chemotherapy-induced neutropenia (CIN).
G-CSF) signed an exclusive strategic cooperation agreement in China
.
According to the agreement, Yiyi Bio will exclusively authorize the Chinese commercialization rights of the new biological drug F-627 to Nanjing Shunxin Pharmaceutical Co.
, Ltd.
of China Biopharmaceutical's core subsidiary Chia Tai Tianqing Pharmaceutical Group
.
Yiyi Bio will receive up to 210 million yuan in advance and milestone payments, as well as double-digit tiered net sales royalties.
.
According to data, F-627 (efbemalenograstim alfa) is a bio-innovative drug for neutropenia (CIN) caused by chemotherapy.
It aims to treat cancer patients with neutropenia (CIN) after chemotherapy.
)
.
Analysis believes that the above transactions are actually the epitome of the license-in model becoming a trend in China
.
In recent years, with the normalization of centralized procurement, the pharmaceutical industry has begun to reshuffle its holdings
.
Affected by this, domestic pharmaceutical companies have also begun to passively or actively join the wave of transformation and upgrading, and the enthusiasm for innovative drug research and development is very high
.
However, because the research and development time of innovative drugs is very long, and the cost is also very huge, the "License-in" model is becoming more and more sought after by domestic innovative drug companies, and the transaction volume has begun to continuously record highs
.
It is understood that since the beginning of this year, domestic pharmaceutical companies have spent huge sums of money to introduce innovative drugs has become the norm in the industry, and transactions with hundreds of millions of dollars are not rare
.
In this regard, industry analysts believe that pharmaceutical companies are now vigorously "bringing in", in fact, in order to better "go out"
.
In the future, with the continuous improvement of domestic pharmaceutical companies' innovation capabilities and the continuous emergence of innovative results, more and more high-quality domestic drugs will also go out to seize a larger market and benefit more patients
.
.
However, it is worth noting that although pharmaceutical companies are currently engaged in innovative research and development, due to the uneven innovation and research capabilities of pharmaceutical companies and the huge investment in innovative drug research and development, many companies have also begun to introduce new drugs to enrich their product pipelines.
, And enhance innovation competitiveness
.
For example, Xin Li Thai announced a cooperation with South Korea D&DPharmatech, Inc.
to obtain the exclusive license for its innovative drug DD01 in mainland China
.
It is understood that "DD01" is a long-acting GLP-1R/GCGR dual agonist developed by D&D.
The proposed development indications are type II diabetes, obesity, non-alcoholic steatohepatitis (NASH) and other diseases
.
Currently, DD01 is conducting a phase I clinical trial in the United States with subjects with non-alcoholic fatty liver disease and obese type 2 diabetes
.
According to the announcement, after the start of the cooperation, Xinlitai will use self-raised funds to pay according to the development milestone.
The total amount is expected to be less than 27 million U.
S.
dollars (a total of approximately RMB 175.
5 million, subject to the exchange rate conversion amount at the time of actual investment)
.
Coincidentally, not long before this, Yiyi Biosciences and CP Tianqing Nanjing Shunxin jointly announced the new biological drug F-627 (Aibeguestine α, long-acting) for the treatment of chemotherapy-induced neutropenia (CIN).
G-CSF) signed an exclusive strategic cooperation agreement in China
.
According to the agreement, Yiyi Bio will exclusively authorize the Chinese commercialization rights of the new biological drug F-627 to Nanjing Shunxin Pharmaceutical Co.
, Ltd.
of China Biopharmaceutical's core subsidiary Chia Tai Tianqing Pharmaceutical Group
.
Yiyi Bio will receive up to 210 million yuan in advance and milestone payments, as well as double-digit tiered net sales royalties.
.
According to data, F-627 (efbemalenograstim alfa) is a bio-innovative drug for neutropenia (CIN) caused by chemotherapy.
It aims to treat cancer patients with neutropenia (CIN) after chemotherapy.
)
.
Analysis believes that the above transactions are actually the epitome of the license-in model becoming a trend in China
.
In recent years, with the normalization of centralized procurement, the pharmaceutical industry has begun to reshuffle its holdings
.
Affected by this, domestic pharmaceutical companies have also begun to passively or actively join the wave of transformation and upgrading, and the enthusiasm for innovative drug research and development is very high
.
However, because the research and development time of innovative drugs is very long, and the cost is also very huge, the "License-in" model is becoming more and more sought after by domestic innovative drug companies, and the transaction volume has begun to continuously record highs
.
It is understood that since the beginning of this year, domestic pharmaceutical companies have spent huge sums of money to introduce innovative drugs has become the norm in the industry, and transactions with hundreds of millions of dollars are not rare
.
In this regard, industry analysts believe that pharmaceutical companies are now vigorously "bringing in", in fact, in order to better "go out"
.
In the future, with the continuous improvement of domestic pharmaceutical companies' innovation capabilities and the continuous emergence of innovative results, more and more high-quality domestic drugs will also go out to seize a larger market and benefit more patients
.
